RECITALSLicense and Research Agreement • September 15th, 2000 • Rigel Pharmaceuticals Inc • Services-commercial physical & biological research • California
EX-10.30 8 kite-ex1030_304.htm EX-10.30 License and research AGREEMENTLicense and Research Agreement • May 5th, 2020 • New York
This License and Research Agreement (the “Agreement”) is effective as of October 26, 2015 (the “Effective Date”) by and between Alpine Immune Sciences, Inc., a Delaware corporation located at 600 Stewart Street, Suite 1503, Seattle, WA 98101 (“Alpine”), and Kite Pharma, Inc., a Delaware corporation located at 2225 Colorado Avenue, Santa Monica, CA 90404 (“Kite”). Alpine and Kite are referred to individually as a “Party” and collectively as the “Parties”.
LICENSE AND RESEARCH AGREEMENT BETWEEN ANTIGEN EXPRESS, INC. (A WHOLLY-OWNED SUBSIDIARY OF GENEREX BIOTECHNOLOGY CORPORATION) AND SHENZHEN BIOSCIEN PHARMACEUTICALS CO. LTD. November 29th, 2017License and Research Agreement • July 23rd, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • New York
This License and Research Agreement (the "Agreement"), effective as of the day of November, 2017 (the "Effective Date"), is by and between Antigen Express, Inc., a wholly-owned subsidiary of Generex Biotechnology Corporation, a Delaware corporation, with an address of 4145 North Service Road, Suite 200, Burlington, Ontario, Canada L7L 6A3 (hereinafter referred as "Licensor"), and Shenzhen BioScien Pharmaceuticals Co., Ltd., located at Room 311, First Building, Shenzhen Overseas Venture Park (Longgang), Shenzhen 518116, Guangdong, China (hereinafter referred to as "Licensee"). Licensor and Licensee may each be referred to herein individually as a "Party" and collectively
BACKGROUNDLicense and Research Agreement • May 23rd, 2000 • Genometrix Inc • Services-commercial physical & biological research
LICENSE AND RESEARCH AGREEMENT BY AND BETWEEN CALITHERA BIOSCIENCES INC. AND HIGH POINT PHARMACEUTICALS, LLC TRANSTECH PHARMA LLC DATED AS OF MARCH 5, 2015License and Research Agreement • July 23rd, 2015 • vTv Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE AND RESEARCH AGREEMENT is entered into this 5th day of March, 2015 (the “Effective Date”) by and between Calithera Bioscience Inc., a corporation organized under the laws of the State of Delaware, having a business address at 343 Oyster Point Blvd #200, South San Francisco, CA 94080 (“Calithera”), on the one hand, and High Point Pharmaceuticals, LLC, a company organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, NC 27265 (“HPP”) and TransTech Pharma LLC, a company organized under the laws of the State of Delaware, having a business address at 4170 Mendenhall Oaks Parkway, High Point, NC 27265 (“TransTech” and collectively with HPP, “High Point”), on the other hand.
LICENSE AND RESEARCH AGREEMENTLicense and Research Agreement • October 24th, 2017 • Alpine Immune Sciences, Inc. • Pharmaceutical preparations
If any milestone event is achieved for a Licensed Product before any of the preceding milestone events are achieved for such Licensed Product, then all the milestone payments for such unachieved preceding milestone events will be due and payable with the milestone payment for the milestone event that was achieved. For example, if Regulatory Approval for a Licensed Product is achieved from a [****] without the need to conduct a [****], then the milestone payment of $[****] would be payable along with the milestone payment of $[****] for such Licensed Product.
ACBSCT 2020License and Research Agreement • September 22nd, 2020
• License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers.
LICENSE AND RESEARCH AGREEMENT (Amended and Restated)License and Research Agreement • November 13th, 2001 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • California
This License And Research Agreement (the “Agreement”) is made and entered into as of September 2, 1999, (the “Effective Date”), as first amended and restated on March 26, 2001 and again amended and restated on July 1, 2001 (the “Restatement Date”), by and between Rigel Pharmaceuticals, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 240 East Grand Avenue, South San Francisco, CA 94080 (“Rigel”) and Cell Genesys, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 342 Lakeside Drive, Foster City, CA 94404 (“CG”). Rigel and CG may be referred to collectively as the “Parties,” or individually as a “Party.”
LICENSE AND RESEARCH AGREEMENT (Amended and Restated)License and Research Agreement • November 8th, 2005 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS LICENSE AND RESEARCH AGREEMENT (the “Agreement”) is made and entered into as of September 2, 1999, (the “Effective Date”), as amended and restated on March 26, 2001 (the “Restatement Date”), by and between Rigel Pharmaceuticals, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 240 East Grand Avenue, South San Francisco, CA 94080 (“Rigel”) and Cell Genesys, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 342 Lakeside Drive, Foster City, CA 94404 (“CG”). Rigel and CG may be referred to collectively as the “Parties,” or individually as a “Party.”
ContractLicense and Research Agreement • October 28th, 2021 • Agendia N.V. • Services-medical laboratories
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed.
ACBSCT 2020License and Research Agreement • February 17th, 2021
• License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers.
LICENSE AND RESEARCH AGREEMENTLicense and Research Agreement • May 12th, 2008 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Research Agreement (together with all Exhibits, Schedules and other attachments hereto, this “Agreement”), is dated as of the 7th day of January, 2008 (the “Execution Date”), by and between Genzyme Corporation, a Massachusetts corporation (“Genzyme”) and Isis Pharmaceuticals, Inc., a Delaware corporation (“Isis”). Genzyme and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.”
LICENSE AND RESEARCH AGREEMENT AMENDMENT NO. 1License and Research Agreement • October 24th, 2017 • Alpine Immune Sciences, Inc. • Pharmaceutical preparations
This License and Research Agreement Amendment No. 1 (this “Amendment No. 1”) is made effective as of October 20, 2017 (the “Amendment Effective Date”) by and between AIS Operating Co., Inc., f/k/a Alpine Immune Sciences, Inc., a Delaware corporation (“Alpine”), and Kite Pharma, Inc., a Delaware corporation (“Kite”), with reference to the following facts:
LICENSE AND RESEARCH AGREEMENT BY AND BETWEEN CALITHERA BIOSCIENCES INC. AND HIGH POINT PHARMACEUTICALS, LLC TRANSTECH PHARMA LLC DATED AS OF MARCH 5, 2015License and Research Agreement • May 11th, 2015 • Calithera Biosciences, Inc. • Pharmaceutical preparations • Delaware
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
LICENSE AND RESEARCH AGREEMENTLicense and Research Agreement • March 16th, 2007 • Diversa Corp • Services-commercial physical & biological research • New York
THIS LICENSE AND RESEARCH AGREEMENT (the “Agreement”) is entered into as of December 31, 2006 (the “Effective Date”) by and between SYNGENTA PARTICIPATIONS AG, a corporation organized under the laws of Switzerland (“Syngenta”), and DIVERSA CORPORATION, a Delaware corporation (“Diversa”). In this Agreement, Syngenta and Diversa are each referred to individually as a “Party” and collectively as the “Parties.”
LICENSE AND RESEARCH AGREEMENT AMENDMENT NO. 2License and Research Agreement • March 18th, 2019 • Alpine Immune Sciences, Inc. • Pharmaceutical preparations
This License and Research Agreement Amendment No. 2 (this “Amendment No. 2”) is made effective as of October 17, 2018 (the “Amendment Effective Date”) by and between AIS Operating Co., Inc., f/k/a Alpine Immune Sciences, Inc., a Delaware corporation (“Alpine”), and Kite Pharma, Inc., a Delaware corporation (“Kite”), with reference to the following facts:
LICENSE AND RESEARCH AGREEMENT (Amended and Restated)License and Research Agreement • May 14th, 2001 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • California
This License And Research Agreement (the "Agreement") is made and entered into as of September 2, 1999, (the "Effective Date"), as amended and restated on March 26, 2001 (the "Restatement Date"), by and between Rigel Pharmaceuticals, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 240 East Grand Avenue, South San Francisco, CA 94080 ("Rigel") and Cell Genesys, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 342 Lakeside Drive, Foster City, CA 94404 ("CG"). Rigel and CG may be referred to collectively as the "Parties," or individually as a "Party."
Developing Off-The-Shelf CAR NK Cells Targeting CD70:License and Research Agreement • October 27th, 2024
LICENSE AND RESEARCH AGREEMENT BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, AMR TECHNOLOGY, INC., AND ALBANY MOLECULAR RESEARCH, INC. EXECUTED: OCTOBER 20, 2005License and Research Agreement • March 16th, 2006 • Albany Molecular Research Inc • Services-commercial physical & biological research • New York
This License and Research Agreement (this “Agreement”) is made by AMR Technology, Inc., a corporation organized and existing under the laws of Vermont and having a principle place of business at 5429 Main Street, Manchester, Vermont, Albany Molecular Research, Inc., a corporation organized and existing under the laws of the State of Delaware and having a principle place of business at 21 Corporate Circle, Albany, New York 12203 (with “AMRI” meaning individually and collectively AMR Technology, Inc. and Albany Molecular Research, Inc.) and Bristol-Myers Squibb Company, a corporation organized and existing under the laws of the State of Delaware and headquartered at 345 Park Avenue, New York, New York 10154 USA (“BMS”).
